Evidence map›Paper›PMID 35154101›Full record

ArticleFrontiers in immunology2022

Identification of a Novel Nomogram to Predict Progression Based on the Circadian Clock and Insights Into the Tumor Immune Microenvironment in Prostate Cancer.

Dechao Feng, Qiao Xiong, Facai Zhang, Xu Shi, Hang Xu, Wuran Wei, Jianzhong Ai, Lu Yang

Abstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Circadian clock and cancer.Military Medical Research · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Unraveling links between aging, circadian rhythm and cancer: Insights from evidence-based analysis.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024
    Article
  16. Article
  17. Article
  18. Biological clock regulation by theFrontiers in cell and developmental biology · 2024
    Review
  19. c-Jun N-terminal kinase signaling in aging.Frontiers in aging neuroscience · 2024
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dechao FengDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Qiao XiongDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Facai ZhangDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Xu ShiDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Hang XuDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Wuran WeiDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Jianzhong AiDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Lu YangDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Currently, the impact of the circadian rhythm on the tumorigenesis and progression of prostate cancer (PCA) has yet to be understood. In this study, we first established a novel nomogram to predict PCA progression based on circadian clock (CIC)-related genes and provided insights into the tumor immune microenvironment. Methods: The TCGA and Genecards databases were used to identify potential candidate genes. Lasso and Cox regression analyses were applied to develop a CIC-related gene signature. The tumor immune microenvironment was evaluated through appropriate statistical methods and the GSCALite database. Results: Ten genes were identified to construct a gene signature to predict progression probability for patients with PCA. Patients with high-risk scores were more prone to progress than those with low-risk scores (hazard ratio (HR): 4.11, 95% CI: 2.66-6.37; risk score cut-off: 1.194). CLOCK, PER (1, 2, 3), CRY2, NPAS2, RORA, and ARNTL showed a higher correlation with anti-oncogenes, while CSNK1D and CSNK1E presented a greater relationship with oncogenes. Overall, patients with higher risk scores showed lower mRNA expression of PER1, PER2, and CRY2 and higher expression of CSNK1E. In general, tumor samples presented higher infiltration levels of macrophages, T cells and myeloid dendritic cells than normal samples. In addition, tumor samples had higher immune scores, lower stroma scores and lower microenvironment scores than normal samples. Notably, patients with higher risk scores were associated with significantly lower levels of neutrophils, NK cells, T helper type 1, and mast cells. There was a positive correlation between the risk score and the tumor mutation burden (TMB) score, and patients with higher TMB scores were more prone to progress than those with lower TMB scores. Likewise, we observed similar results regarding the correlation between the microsatellite instability (MSI) score and the risk score and the impact of the MSI score on the progression-free interval. We observed that anti-oncogenes presented a significantly positive correlation with PD-L1, PD-L2, TIGIT and SIGLEC15, especially PD-L2. Conclusion: We identified ten prognosis-related genes as a promising tool for risk stratification in PCA patients from the fresh perspective of CIC.

Indexed as

NomogramsTranscriptomeBiomarkers, TumorCircadian ClocksCircadian RhythmGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleOncogenesPrognosisProstatic NeoplasmsRisk FactorsTumor MicroenvironmentBiomarkers, Tumorcircadian clockcircadian rhythmgene signaturepredictive modeltargeted therapytumor immune microenvironment

Identifiers

PMID35154101
PMCPMC8829569

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.